Given the lack of positive impact on infant mortality after three decades of working to address perinatal risk by telling pregnant women not to smoke, to get prenatal care and so forth, medical educators and researchers are exploring other preconception factors, including family planning. After all, women with planned pregnancies are more likely to be nutritionally fit, engage in healthy behaviors and attend prenatal care. They are less likely to have preterm births.
Preterm birth is a significant risk factor for infant mortality, and mothers who have already had one preterm baby are more likely to have another premature delivery. Research exploring how to reduce preterm births found that weekly injections of 17 Alpha-Hydroxyprogesterone Caproate (250 mg)—from 16 weeks until delivery (or 36 weeks)—decreases the risk of recurrent preterm births by 30 to 40 percent. But a range of on-the-ground hurdles prevent universal adoption.
Healthcare-delivery system issues include how to identify eligible women and reach them with information about the treatment. Access to progesterone through local clinics and transportation to sites to receive the weekly injections also present barriers. Other issues relate to prior authorization requirements by payers and a lack of low-cost alternative (generic) to the brand drug.